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Abstract
Downbeat nystagmus (DBN) is a frequent form of acquired persisting central fixation nystagmus, often associated with other
cerebellar ocular signs, such as saccadic smooth pursuit or gaze-holding deficits. Despite its distinct clinical features, the
underlying etiology of DBN often remains unclear. Therefore, a genome-wide association study (GWAS) was conducted in
106 patients and 2609 healthy controls of European ancestry to identify genetic variants associated with DBN. A genome-wide
significant association (p < 5 × 10−8) with DBNwas found for a variation on chromosome 13 located within the fibroblast growth
factor 14 gene (FGF14). FGF14 is expressed in Purkinje cells (PCs) and a reduction leads to a decreased spontaneous firing rate
and excitability of PCs, compatible with the pathophysiology of DBN. In addition, mutations in the FGF14 gene cause
spinocerebellar ataxia type 27. Suggestive associations (p < 1 × 10−05) could be detected for 15 additional LD-independent loci,
one of which is also located in the FGF14 gene. An association of a region containing the dihydrofolate reductase (DHFR) and
MutS Homolog 3 (MSH3) genes on chromosome 5 was slightly below the genome-wide significance threshold. DHFR is
relevant for neuronal regulation, and a dysfunction is known to induce cerebellar damage. Among the remaining twelve
suggestive associations, four genes (MAST4, TPPP, FTMT, and IDS) seem to be involved in cerebral pathological processes.
Thus, this GWAS analysis has identified a potential genetic contribution to idiopathic DBN, including suggestive associations to
several genes involved in postulated pathological mechanisms of DBN (i.e., impaired function of cerebellar PCs).
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Introduction
There is a wide range of hereditary and non-hereditary cere-
bellar ataxias (CA) with variable clinical symptoms, usually
characterized by gait and limb ataxia, dysarthria, and oculo-
motor disorders, such as gaze-evoked nystagmus or saccadic
smooth pursuit [1]. Althoughmany genetic causes of CA have
been discovered in recent years [2], several cases remain
idiopathic. Unknown genetic factors and genetic susceptibility
factors have been suggested as contributing to the degenera-
tion of the cerebellum [2, 3].
Although downbeat nystagmus (DBN) is the most com-
mon involuntary fixation nystagmus [4], it is a very rare sign.
DBN is often associated with other cerebellar ocular signs
such as saccadic smooth pursuit or gaze-holding deficits (for
ref. see [5, 6]). The most common symptoms of DBN are
unsteadiness of gait (89% idiopathic DBN vs. 81% secondary
DBN) and oscillopsia (44% vs. 38%) [4]. It is most often
caused by a bilateral hypofunction of the flocculus or
paraflocculus [7, 8] which – due to an impaired function of
the Purkinje cells (PCs) – causes a disinhibition of superior
vestibular nuclei neurons, leading to a slow upward drift of the
eyes and a quick downward saccade [9]. Several theories
concerning the pathophysiology of DBN have been proposed:
(A) an asymmetry of peripheral vestibular input [10], (B) a
central imbalance in the vertical vestibulo-ocular system [9,
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11], (C) an imbalance of the smooth pursuit system [7, 12],
and (D) a mismatch of the coordinate system of burst gener-
ator and the vertical generator [13].
In many cases, the etiology remains unclear (so-called id-
iopathic DBN: 38%); in other cases, an underlying structural
pathology can be found, such as degenerative disorders of the
cerebellum (20%), vascular lesions (9%), and malformations
(7%) [4]. DBN is also frequently found in patients with
spinocerebellar ataxia type 6 (SCA6) as well as in episodic
ataxia type 2 (EA2) [14], whereas DBNwas not found in other
genetic CA such as SCA1, SCA2, SCA3, and SCA 31
[15–17]. All in all, despite its high prevalence and its charac-
teristic clinical features which allow diagnosis, the underlying
etiology of DBN often remains unclear.
Therefore, we used a different approach and performed a
genome-wide association study (GWAS) in patients with idi-
opathic DBN in order to identify genes which might be asso-
ciated with the disease and to allow a further evaluation of the
pathophysiology and etiology of DBN.
Material and Methods
Patients
Patients of European descent were recruited in the German
Center for Vertigo and Balance Disorders and the
Department of Neurology at the Ludwig Maximilians
University (LMU), Munich from 2012 to 2017. The detailed
medical history, medication, and harmful substance abuse of
each participant were assessed using a semi-structured inter-
view. In addition, a detailed family history of first-degree rel-
atives was collected, focusing in particular on neurological
genetic disorders and DBN. None of the DBN patients report-
ed cerebellar disorders in the parent generation. All patients
underwent an extensive neurological examination and cere-
bral imaging by MRI or CT. Any evidence of symptomatic
DBN led to exclusion from the study (see 2.1.2).
Inclusion Criteria
All patients included showed DBN, which has been de-
fined as downwardly beating fixation nystagmus in pri-
mary position with an increase of the intensity of the
nystagmus during lateral and downward gaze. The pa-
tients included in this study can be divided into two
subgroups: (1) idiopathic DBN in association with other
cerebellar oculomotor disorders (85 patients); and (2)
idiopathic DBN in association with other cerebellar dis-
orders such as cerebellar ataxia or with cerebellar atro-
phy (21 patients).
Exclusion Criteria
Subjects with any evidence of symptomatic DBN were ex-
cluded. This included cerebellar/brainstem infarction or hem-
orrhage; cerebellar tumor; evident neurodegenerative cerebral
disorders/syndromes (e.g., multiple system atrophy); inflam-
matory, infectious, and immune-mediated cerebellar damage;
toxic and nutritional cerebellar damage (e.g., due to alcohol);
paraneoplastic cerebellar degeneration; or other infratentorial
structural lesions.
Healthy Volunteers (PAGES)
Healthy volunteers were recruited to the PAGES (Phenomics
and Genomics Sample) sample from the Munich greater area
and were of German descent. PAGES consists of approxi-
mately 3000 healthy individuals with a detailed medical, neu-
rological, and psychiatric history of the participants them-
selves, and their first-degree relatives who were assessed
using semi-structured and comprehensive interviews includ-
ing the Structured Clinical Interview for DSM-IV (SCID I, II)
[18, 19] and the Family History Assessment Module [20].
Individuals suffering from psychiatric or neurological diseases
as well as subjects with CNS impairment or a self-reported
history of DBN were excluded.
Genotyping
Genomic DNA was extracted from whole blood using the
QIAamp DNA Maxi Kit (Qiagen), according to the manufac-
turer’s instructions and dissolved in nuclease-free water. The
concentration of genomic DNA was measured using
Picogreen (Molecular Probes) and adjusted to 50 ng/μl.
Samples were genotyped on different platforms.
Genome-Wide Association Analysis
Genotyping and association analysis were performed as pre-
viously described [21].
Overview
Genotypes of the different platforms were imputed in seven
batches and combined into one large dataset. Quality control
and imputation of batch 1 (Human610-Quad [22],
Human660W-Quad [23]), batch 2 (HumanHap300 [24]),
and batch 3 (Affymetrix 6.0 [25]) were performed in the
framework of a schizophrenia meta-analysis conducted by
the Psychiatric Genomics Consortium (PGC) [26]. Batches 4
(HumanHap300 [27]), 5 (Illumina HumanOmniExpress-12
[ 2 8 ] ) , 6 ( I l l um i n a Omn i 1 -Quad [ 2 9 ] ) , a n d 7
(HumanOmniExpress-24) were processed following quality
control and imputation protocols, used by the PGC. Datasets
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were combined to get a sufficient number of controls. For
GWAS analysis, selected patients and controls were extracted
from the combined dataset after global quality control [21].
Global Quality Control
PLINK 1.9 [30] was used for global quality control of the
genotype data. A pre-QC filtered SNV (single nucleotide var-
iant) set (missingness < 0.05) was used to exclude subjects
with mismatches between reported and estimated gender and
samples with call rates below a chip-specific threshold.
Sample call rate thresholds differed slightly between chips to
account for smaller sample sizes (96–99%). After subject re-
moval, SNV quality was assessed, and variations were exclud-
ed based on the following criteria: SNV call rate < 99%, de-
viations from Hardy-Weinberg equilibrium in controls (p ≤
10−6) or cases (p ≤ 10−10) and SNVs with call rate differences
≥ 0.02 between cases and controls. Also, x-chromosomal
markers with a haploid heterozygosity rate > 2%, missingness
≥ 0.05, or HWE p ≤ 10−6 in females were removed. A more
stringent quality-controlled (MAF ≥ 0.05, HWE p ≥ 0.05, call
rate ≥ 0.99) and LD-pruned autosomalmarker set was used for
cryptic relatedness, heterozygosity deviation and population
stratification analyses. The marker set was pruned with
PLINK’s indep-pairwise command using r2 = 0.2, a window
size of 1500 and shifting the window 150 SNVs at each step.
Additionally, several high LD regions were excluded as the
extended MHC region. One subject of each pair with
π̂ > 0.1875 was removed; cases were generally preferred over
controls. As sample contamination results in an increase of
heterozygote calls and thereby an overestimation of cryptic
relatedness, individuals showing a heterozygosity deviation
with |Fhet| ≥ 0.2 were excluded. In addition, the number of
π̂-values > 0.05 per individual and the distribution of π̂means
were used to check for outliers and possible sample contami-
nation. Population stratification analysis was done with
EIGENSTRAT [31]. SNV loadings were checked for normal-
ity, and the derived principal components were used to iden-
tify and remove outlying samples. Known duplicates on dif-
ferent chips were checked for concordance, keeping the sam-
ple of higher quality (i.e., sample call rate and overall chip
quality). Both subjects were excluded if the concordance rate
was lower than 99%.
Pre-Phasing and Imputation
Each batch was pre-phased with SHAPEIT [32] and imputed
separately on the 1000 Genomes reference panel phase 1 ver-
sion 3 macGT1 (https://mathgen.stats.ox.ac.uk/impute/data_
download_1000G_phase1_integrated.html) in chunks of
3 Mb using IMPUTE2 [33]. Chromosome X imputation was
performed separately for males and females. After imputation,
the seven batches were combined by retaining markers with
INFO values ≥ 0.6 in every batch and the combined set.
Additionally, all markers with allele frequency differences >
0.1 between any of the batches were excluded. Checks for
cryptic relatedness, heterozygosity deviation, and population
stratification on the combined set were performed, as
described before, using the same exclusion criteria on a
stringent-thresholded marker set (INFO > 0.8, missingness <
1%,MAF > 0.05) for calling best guess genotypes with uncer-
tainty ≤ 0.1.
GWAS Analysis
The final mega dataset was comprised of 4575 individuals,
including 107 DBN patients and 2618 healthy controls appro-
priate for association analysis spread across 6 batches
(Table 1). The principal components for genome-wide associ-
ation analysis were derived by EIGENSTRAT [31]; 1 outlying
case and 9 controls were removed. Tracy-Widom statistics
identified PC1 and PC2 as relevant (Fig. 1). As DBN cases
were typed on one platform, controls of the six batches were
used for batch effect detection. Any marker showing devia-
tions between any of the batches was excluded (logistic re-
gression corrected for PC1 and PC2, p < 0.001). After exclu-
sion of 116,387 variants, the final dataset was comprised of
7,759,885 markers.
GWAS association testing of approximately 8 million var-
iants (INFO ≥ 0.6, MAF ≥ 0.01 in cases and controls) using
106 patients with DBN and 2609 healthy subjects was con-
ducted in PLINK 1.9 [30], applying an additive logistic re-
gression model corrected for age, sex, PC1, and PC2.
Quantile-quantile and Manhattan plots are shown (Figs. 2
and 3). The genomic inflation factor was 1, thus showing no
sign of global inflation due to batch effects or population
stratification. Results were clumped with PLINK to derive
LD-independent index SNVs (3000 kb, p1 = 5 × 10−08, p2 =
1 × 10−4, r2 < 0.1).




Batch N N controls N cases
1 319 0 0
2 709 262 0
3 954 925 0
4 287 99 0
5 607 578 0
6 352 267 0
7 1347 478 106
Combined 4575 2609 106
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Results
One hundred and six patients with idiopathic DBN (46 females,
43%) and 2609 healthy controls (1402 females, 54%) were in-
cluded in the analysis. The mean age of the patients was 70.09 ±
10.1 years; the mean age of the controls was 47.41 ± 16.6 years.
Among approximately 8 million variants tested for association,
we identified one genome-wide associated SNV (p< 5 × 10−8)
located in the fibroblast growth factor 14 gene (FGF14) mapping
to chromosome 13q33.1 (Figs. 2 and 3, Table 2).
In addition, 15 LD-independent loci with suggestive evi-
dence of association (p < 1 × 10−5) were identified. On
Fig. 1 Scatterplot of the first two
principal components (PC)
derived by EIGENSTRAT
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Fig. 2 Manhattan plot of the genome-wide association analysis of 106 DBN cases and 2609 controls. The x-axis shows the chromosomal position, and
the y-axis shows the significance of association (−log10(p)). The red line shows the genome-wide significance level (5 × 10−8)
chromosome 13q33.1 and chromosome 5q14.1, two regions
each were merged on account of physically mapping next to
each other with a distance below 250 kb, resulting in 14 phys-
ically and LD-independent regions (Table 2).
The merged region on chromosome 13 contained parts of
the FGF14 gene, with the genome-wide associated variant
rs72665334 (p = 1.50 × 10−8) being localized in intron 9 and
the suggestive variant chr13_103023008_D (p = 4.52 × 10−5)
in intron 1 of the gene (Fig. 4a). These hits showed isolated
signals and should therefore be interpreted with caution.
The most promising region with suggestive evidence for
association is localized on chromosome 5q14.1 containing
two genes with a head-to-head overlap of their respective
exons 1: dihydrofolate reductase (DHFR) and mutS
(Mutator S) protein homolog 3 (MSH3). Two LD-
independent hits are present in this merged region. Variant
rs245100 (p = 5.03 × 10−07) is located in intron 4 of the
DHFR gene, and rs33003 (p = 3,87 × 10−06) is located in in-
tron 23 of the MSH3 gene (Fig. 4b).
Another four regions with suggestive evidence were also
located on chromosome 5. Apart from one region on chromo-
some 5q23.1 in which the index SNV was located approxi-
mately 300 kb away from the next protein coding gene
(Ferritin Mitochondrial, FTMT), the index SNVs of the re-
maining three regions were located directly in a protein coding
gene: tubulin polymerization promoting protein (TPPP) on
5p15.33, microtubule-associated serine/threonine kinase fam-
ily member 4 (MAST4) on 5q12.3 and ATPase phospholipid
transporting 10B (putative) (ATP10B) on 5q34. As the varia-
tion allocated to ATB10B was a single signal, this has to be
considered with caution. The same applies to the variations on
chromosomes 1p35.2 (long intergenic nonprotein coding
RNA 1648, LINC01648), 2p12 (regenerating family member
1 alpha, REG1A), 3p14.2 (synaptoporin, SYNPR), and
4p16.1 (SH3 domain and tetratricopeptide repeats 1,
SH3TC1). The remaining suggestive signals are localized
near N-acetylated alpha-linked acidic dipeptidase-like 2
(NAALADL2) on chromosome 3q26.31, spermatogenesis-
associated 19 (SPATA19) on chromosome 11q25, Down syn-
drome critical region 4 (DSCR4) on chromosome 21q22.13,
and iduronate 2-sulfatase (IDS) on the X-chromosome
(Xq28).
Discussion
In this study we used a genome-wide approach to detect com-
mon variations associated with DBN. Among the approxi-
mately 8 million SNVs tested, only rs72665334 allocated to
FGF14 on chromosome 13q33.1 remained genome-wide sig-
nificant (p < 5 × 10−8). Additional suggestive associations
(p < 1 × 10−5) were found for 15 LD-independent regions,
the most promising of which were localized on chromosome
5q14.1 in a region containing the two overlapping genes
DHFR and MSH3.
FGF14, the gene underlying the genome-wide hit, is part of
the fibroblast growth factor (FGF) family subgroup of intra-
cellular nonsecretory forms and is involved in the regulation
of voltage-gated ion channels in neurons. It is prominently
expressed in PCs, particularly in the axon initial segment of
these cells [34] modulating the density of sodium [35, 36] and
potassium channels [37] and also has a regulatory effect on
calcium channels [38]. FGF14 knockdown in mouse cerebel-
lar lysates has been shown to affect multiple kinetic parame-
ters in PCs, which are responsible for sodium channel inacti-
vation and thereby decrease the ability of repetitive firing [36,
39]. Also, a reduction of the spontaneous firing rate following
in vivo knockdown of FGF14 in mature cerebellar PCs of
wild-type mice as well as a reduced excitability of these cells
in FGF14 knockout mice could be observed. Subsequently,
these mice showed impairment of motor coordination and
balance [40].
An impaired function of PCs due to reduced excitability is
also compatible with the mode of action of the potassium
channel blocker 4-aminopyridine, the drug of choice for the
treatment of DBN [41, 42] which increases the excitability of
PCs [43]. The same applies to the 4-aminopyridine treatment
of episodic ataxia type 2 (EA2), which is also associated with
DBN [44, 45].
In addition to the already known physiological functions,
mutations in FGF14 have been shown to cause autosomal
dominant spinocerebellar ataxia 27 (SCA27), a rare inherited
neurodegenerative disorder leading to cerebellar degeneration
and clinically slow progressive cerebellar ataxia, oculomotor
deficits including nystagmus, low performance in education,
and mental retardation [46–48].
Fig. 3 Quantile-quantile plot of GWAS analysis. The area shaded in gray
indicates the 95% confidence interval under the null
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However, as LD-dependent variations in this region are
sparse and associations of them are below a suggestive thresh-
old, this result should be considered with caution.
The top hit (rs245100) in the combined region on
chromosome 5q14.1, containing the genes DHFR and
MSH3, is localized in intron 4 of DHFR, and its sig-
nificance was slightly below the genome-wide threshold
(p = 5.03 × 10−7). DHFR is an essential enzyme in the
folate metabolism, which catalyzes the reduction of
dihydrofolate to tetrahydrofolate and additionally, in a
less efficient reaction, the reduction of folate to
dihydrofolate [49]. Folates play an important role in
single carbon metabolism, such as DNA synthesis and
methylation, regulation of gene expression, and synthe-
sis of amino acids, nucleic acids, and neurotransmitters
[50]. There is also evidence of pro-regenerative effects
of folate in the adult CNS [51], as well as on peripheral
neurons [52] which depend essentially on DHFR [53].
Blocking DHFR function by administration of the folate
analogue and DHFR antagonist methotrexate (MTX)
leads to neurotoxic effects in the cerebellum of newborn
rats [54] as well as to the degeneration of PCs in guin-
ea pigs, which could be rescued by application of the
tetrahydrofolate derivative leucovorin [55]. This rescue
effect of folate is also apparent in newborn rats, in
which PC atrophy and cerebellar degenerative changes
induced by treatment with valproic acid in the mothers
could be markedly reduced by an additional treatment
with folic acid [56]. Conceivably, an impaired DHFR
function may contribute to impaired cerebellar function.
The other gene in this chromosomal region is MSH3,
a part of the post-replicative DNA mismatch repair sys-
tem, which is important for cell cycle regulation, apo-
ptosis, and genome stability [57]. Additionally, MSH3
Table 2 LD-independent SNVassociations for DBN
Chr. (region) SNV A1/2 Info Frqcon Frqcase OR
(95% CI)
p value Gene (dist.)
Chr. 13
102,703,679–103,052,397


























































































Genome-wide significant association is shown on top (p value in bold); otherwise, SNVs are sorted by genomic position according to UCSC hg19/NCBI
build 37. The deletion variant is given in the form “chromosome_position_deletion.” Column A12 contains the SNV alleles, with the first allele (A1)
depicting the reference allele for the frequency (Frq) and odds ratio (OR) of A1.CI is the confidence interval, gene is the next gene, dist. is the distance to
index SNV in bp. Chromosome (Chr.) and position denote the associated region surrounding the index SNV containing SNVs in LD (r2 > 0.6) with the
index SNV. Two LD-independent regions were merged on account of a distance below 250 kb (shaded in gray)
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Fig. 4 Regional association plots for loci associated with DBN. In order
to highlight the statistical strength of the association in the context of the
surroundingmarkers, gene annotations and estimated recombination rates
(NCBI build 37) of the SNPs in the specific regions are plotted against
their corresponding p values (as −log10 values, left-hand y-axis). A purple
diamond represents the SNP with the highest association signal in each
locus. All other SNPs are represented as single dots, where dot colors
indicate the LD with the associated SNP. Color coding represents the r2
value, and respective categories are shown on the upper left hand side.
Estimated recombination rates (cM/Mb) are plotted to reflect the local LD
structure surrounding the associated SNP and are shown as vertical light
blue lines, marked on the right-hand y-axis. Genes in the region are
displayed below. The orientation of the genes is indicated by arrows. a
Regional association plot of the FGF14 variations on chromosome
13q33.1 associated with DBN. The genome-wide–associated SNP
(rs72665334, purple diamond) is localized in intron 9, the suggestive
hit chr13_103023008_D (yellow circle) in intron 1 of the fibroblast
growth factor 14 gene (FGF14). LD structure refers to the genome-wide
associated variant rs72665334. b Regional association plot of the merged
region on chromosome 5 containing the overlapping genes DHFR and
MSH3 and the respective hits (rs245100, purple; rs33003, yellow). LD
structure refers to the associated variant localized in DHFR (rs245100)
354 Cerebellum (2020) 19:348–357
has an effect on the phenotype of Friedreich’s ataxia
[58] and Huntington’s disease [59], both trinucleotide
repeat disorders. The process resulting in trinucleotide
repeat (TNR) expansions is not entirely understood,
but MSH3 seems to provide a mutagenic role for
(CTG)n/(CAG)n repeat tracts [60], while knockdown of
Msh3 blocks TNR expansion effectively in mice [61].
Also, the TNR expansion disorder SCA6 frequently ac-
companies DBN [15, 16]. A direct link between the
TNR enhancing properties of MSH3 and the occurrence
of DBN requires further investigation.
In addition to these most promising associations, another
twelve regions with suggestive evidence could be identified.
Five of those variants localized in or near ATP10B,
LINC01648, REG1A, SH3TC1, and SYNPR were single sig-
nals. Taking also into account the relatively low p value, these
signals are probably false positives.
The remaining 7 variants were localized in genes
involved in the cytoskeleton (MAST4, TPPP), iron ho-
meostasis (FTMT), lysosomal degradation of sulfate es-
ters (IDS), glutamate carboxypeptidases (NAALADL2),
and fertility according to their sole expression in repro-
ductive organs (DSCR4, SPATA19). Of these, MAST4
[62], TPPP [63], FTMT [64], and IDS [65] have been
linked to pathological processes in the brain.
Finally, the main limitation of this study is the small
sample size. Since DBN is a very rare phenotype that
has received little attention in research so far, this study
provides first clues to a possible genetic background.
Nevertheless, confirmation of the associated signals in
independent samples is necessary.
In conclusion, a genome-wide significantly associated
signal points to FGF14 as a factor that might be in-
volved in the pathophysiology of DBN. Given the ex-
pression of FGF14 protein in PC, its involvement in the
regulation of neuronal ion channels, and its impact on
the excitability of PCs, together with the hypothesis of
DBN being a consequence of impaired PC function,
these results point to an influence of genetic variations
in FGF14 on the susceptibility of to this typical cere-
bellar nystagmus. The second signal suggests an in-
volvement of the folate metabolism through the associ-
ation of a variation in the regulating enzyme, DHFR.
Both findings provide promising candidates for DBN
and also for cerebellar degeneration as its cause.
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